news

Gilead’s $658.5m immunotherapy collaboration

5
SHARES

Gilead will develop immunotherapy products through a $658.5m agreement with EVOQ Therapeutics using EVOQ’s NanoDisc technology.

Gilead’s $658.5m immunotherapy collaboration - NanoDisc technology

EVOQ Therapeutics Inc has agreed to license its NanoDisc technology for rheumatoid arthritis (RA) and lupus to Gilead Sciences, Inc, enabling EVOQ to potentially receive up $658.5 million. The companies will collaborate to advance preclinical development and Gilead will be responsible for clinical development and commercialisation.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

“Despite key advances over the past two decades, there remains significant unmet need for people living with inflammatory and autoimmune diseases,” stated Dr Flavius Martin, Executive Vice President, Research at Gilead. “We are excited to collaborate with EVOQ [in our aim to address] the needs of people living with these conditions.”

EVOQ’s NanoDisc technology for rheumatoid arthritis and lupus

EVOQ’s technology is designed to enable lymph-targeted delivery of disease-specific antigens that have been optimised to deliver antigens to restore immune tolerance. The technology has the potential to change the paradigm for the treatment of autoimmune diseases.

According to EVOQ, it works mainly by activating dendritic cells, found in large quantities in the human lymphatic system. Dendritic cells prime different types of effector T cells to coordinate an immune response either towards immune tolerance or towards immune activation.

Under the terms of the agreement, the sum EVOQ could potentially gain will come from upfront, option exercise and milestone payments across all programmes, as well as tiered royalties on product sales.

Gilead will have the option to exclusively license rights to EVOQ’s NanoDisc technology to pursue product candidates for RA and lupus indications.

Share via
Share via